STAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say
Why it matters: Generic licensing of islatravir could make HIV prevention accessible to millions for under $5 a year.
- Researchers are advocating for Merck to 'urgently begin licensing generic production' of its HIV prevention pill.
- Merck's experimental HIV prevention pill could potentially be produced for less than $5 per year.
- Islatravir is the specific drug being developed by Merck for HIV prevention.
Merck's experimental HIV prevention pill, islatravir, could be manufactured for under $5 annually, according to researchers who are urging Merck to license generic production immediately. This cost-effectiveness highlights a significant opportunity to expand access to crucial HIV prevention globally.
